bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel
Clicks: 198
ID: 212175
2011
Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m2 i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg i.v. every 2 weeks. Results. Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, only five patients had died. The regimen was generally well tolerated. Conclusion. Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.
| Reference Key |
francini2011prostatebevacizumab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Filippo Francini;Alessandra Pascucci;Edoardo Francini;Gianluca Bargagli;Raffaele Conca;Antonella Licchetta;Giandomenico Roviello;Ignazio Martellucci;Giorgio Chiriacò;Salvatora Tindara Miano;Giuseppe Marzocca;Antonio Manganelli;Roberto Ponchietti;Vinno Savelli;Roberto Petrioli |
| Journal | seminars in radiation oncology |
| Year | 2011 |
| DOI | 10.1155/2011/258689 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.